Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)

NCT00005764 is registered in ClinicalTrials.gov with Glaxo Wellcome as lead sponsor.

NCT NCT00005764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)
Lead sponsor
Glaxo Wellcome
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2000
Completion date
Not reported
Enrollment
100
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, lipodystrophy